Drug and disease signature integration identifies synergistic combinations in glioblastoma

Drug and disease signature integration identifies synergistic combinations in glioblastoma

Inherent or acquired resistance to treatment of glioblastoma (GBM) is nearly universal. Here, the authors introduce a platform to identify synergistic drug combinations for patient-specific treatment of GBM based on gene expression signatures and small molecule perturbation-response profiles.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vasileios Stathias, Anna M. Jermakowicz, Marie E. Maloof, Michele Forlin, Winston Walters, Robert K. Suter, Michael A. Durante, Sion L. Williams, J. William Harbour, Claude-Henry Volmar, Nicholas J. Lyons, Claes Wahlestedt, Regina M. Graham, Michael E. Ivan, Ricardo J. Komotar, Jann N. Sarkaria, Aravind Subramanian, Todd R. Golub, Stephan C. Schürer, Nagi G. Ayad
Format: article
Langue:EN
Publié: Nature Portfolio 2018
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/27c294a5f7c843d6a3a8dc34a08977c6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/27c294a5f7c843d6a3a8dc34a08977c6

Documents similaires